Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Immunovant. The associated price target remains the same with $50.00.

Sam Slutsky has given his Buy rating due to a combination of factors tied to Immunovant’s focused execution and advancing late-stage pipeline. He highlights that the company is simultaneously progressing multiple subcutaneous FcRn inhibitor programs, including next-generation IMVT-1402 and first-generation batoclimab, with all key development timelines currently intact. IMVT-1402 is being advanced across six indications, several of which are in potentially registrational settings such as myasthenia gravis, CIDP, Graves’ disease, difficult-to-treat ACPA-positive rheumatoid arthritis, and Sjogren’s, along with an ongoing proof-of-concept study in cutaneous lupus where early open-label experience has been encouraging. This breadth of late-stage activity, coupled with clear visibility on a robust catalyst calendar, underpins his constructive view on the stock.

Slutsky also emphasizes the significance of upcoming 2026 readouts as value inflection points. Data from the difficult-to-treat RA trial are now expected in the second half of 2026 after enrollment finished ahead of schedule, and proof-of-concept results in cutaneous lupus are anticipated in the same timeframe. For batoclimab, concurrent topline data from two potentially registrational thyroid eye disease trials are expected in the first half of 2026, at which point the company will evaluate a path toward a potential marketing application. He notes that the discontinuation of a competitor’s FcRn program in TED could make positive batoclimab data particularly meaningful, both scientifically and commercially. This, together with a solid cash runway and disciplined burn profile, supports his positive stance and underlies the Buy recommendation on Immunovant shares.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMVT in relation to earlier this year.